The Pandemic a Year On

No Comments

Success Stories About COVID-19 Treatment & Vaccine Development

– 1 min read

While the past year has been abnormal and quite challenging, it has been a constant motivation to know that we at ChemoMetec can play a part in the fight against the coronavirus:

1. Early in 2020, we provided the Copenhagen University member of the PREVENT-nCoV consortium with our new automated cell counter to support their development of a COVID-19 vaccine. Now in clinical trial, this vaccine is based on the VLP technology. The PREVENT-nCoV consortium consists of six European institutes and biotech companies.

2. The Méary Center APHP is using our cell counter to develop an MSC-based treatment for patients with respiratory symptoms.

3. The Jenner Institute used our automated cell counter to develop the Oxford/AstraZeneca mRNA-based vaccine which is now being administered to many across the world.

4. Finally in November, we sat down and talked to Drs. Ali Salanti and Max Moscote Søgaard from AdaptVac and ExpreS2ion Biotechnologies respectively, to talk about how to fast-track vaccine development and testing. Their COVID-19 vaccine has been recently (as of March 2021) approved for clinical trials in humans.

covid-19 success stories

Further Reading

By Janny Marie L Peterslund, Scientific Affairs Manager at ChemoMetec
Janny Marie has a background in stem cell research at Novo Nordisk, Denmark. She worked at STEMCELL Technologies, supporting and managing the epithelial cell culture product portfolio. Now at ChemoMetec, Janny Marie supports collaborations with external partners and writes for the Cell Counting Blog. 

BLOG DISCLAIMER

We welcome and encourage blog users to leave comments. ChemoMetec reserves the right to moderate all comments and delete any that could be determined as i) irrelevant; ii) containing spam; iii) containing profanity; iv) deemed offensive or; v) contain questionable content. We reserve the right to withhold any comment from being published. ChemoMetec is not responsible for the content in comments, which represent solely the views of the commenter.

Leave a comment

Your email address will not be published. Required fields are marked *